New crystalline forms of mebendazole with n-alkyl carboxylic acids: Neutral and ionic status

Chinese Journal of Chemistry

Volumn 31, Issue 5, 2013, Pages 635-640

  Chen, Jiamei ^a   Lu, Tongbu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

crystal engineering; crystalline form; hydrogen bond; mebendazole; supramolecular synthon

Indexed keywords

EID: 84878143383     PISSN: 1001604X     EISSN: 16147065     Source Type: Journal    
DOI: 10.1002/cjoc.201300217     Document Type: Article

References (27)

1. Valder, C.; Merrifield, D., Pharmaceutical Technology, SmithKline Beechum RD News, London, 1996.
2. Rodríguez-Spong, B.; Price, C. P.; Jayasankar, A.; Matzger, A. J.; Rodríguez-Hornedo, N.,. Adv. Drug Del. Rev., 2004, 56, 241.
3. Serajuddin, A. T. M.,. Adv. Drug Del. Rev., 2007, 59, 603.
4. Stahl, P. H.; Wermuth, C. G., Handbook of Pharmaceutical Salts: Properties, Selection, and Use, Wiley-VCH, Zurich, 2002.
5. Vishweshwar, P.; McMahon, J. A.; Bis, J. A.; Zaworotko, M. J.,. J. Pharm. Sci., 2006, 95, 499.
6. Trask, A. V.; Motherwell, W. D. S.; Jones, W.,. Cryst. Growth Des., 2005, 5, 1013.
7. Rodríguez-Hornedo, N.; Nehm, S. J.; Jayasankar, A., Encyclopedia of Pharmaceutical Technology, 3 rd ed., Informa Healthcare, London, 2006, p. 615.
8. Schultheiss, N.; Newman, A.,. Cryst. Growth Des., 2009, 9, 2950.
9. Noriyuki, T.,. Pharm. Tech. Japan, 2009, 25, 2543.
10. H?rter, D.; Dressman, J. B.,. Adv. Drug Del. Rev., 2001, 46, 75.
11. Trask, A. V.,. Mol. Pharm., 2007, 4, 301.
12. Allen, L. V.; Popovich, N. G.; Ansel, H. C., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Lippincott Williams and Wilkins, New York, 2005.
13. European Pharmacopoeia, 5 th ed., Council of Europe, Strasbourg, 2008, p. 1981.
14. Himmelreich, M.; Rawson, B. J.; Watson, T. R.,. Aust. J. Pharm. Sci., 1977, 6, 123.
15. Costa, J.; Fresno, M.; Guzman, L.; Igual, A.; Pujol, M.,. Circ. Farm., 1991, 49, 415.
16. Charoenlarp, P.; Waikagul, J.; Muennoo, C.; Srinophakun, S.; Kitayaporn, D.,. Southeast Asian J. Trop. Med. Public Health, 1993, 24, 712.
17. Evans, A. C.; Fincham, J. E.; Dhansay, M. A.; Liebenberg, W.,. S. Afr. Med. J., 1999, 89, 1118.
18. Agatonovic-Kustrin, S.; Glass, B. D.; Mangan, M.; Smithson, J.,. Int. J. Pharmaceut., 2008, 361, 245.
19. Martins, F. T.; Neves, P. P.; Ellena, J.; Camí, G. E.; Brusau, E. V.; Narda, G. E.,. J. Pharm. Sci., 2009, 98, 2336.
20. Chen, J. M.; Wang, Z. Z.; Wu, C. C.; Li, S.; Lu, T. B.,. CrystEngComm, 2012, 14, 6221.
21. CrysAlisPro, Version 1.171.35.19., Agilent Technologies Inc., Santa Clara, CA, USA, 2011.
22. Sheldrick, G. M.,. Acta Cryst. A, 2008, 64, 112.
23. Caira, M. R.; Dekker, T. G.; Liebenberg, W. J.,. Chem. Crystallogr., 1998, 28, 11.
24. Delori, A.; Suresh, E.; Pedireddi, V. R.,. Chem. Eur. J., 2008, 14, 6967.
25. Childs, S. L.; Stahly, G. P.; Park, A.,. Mol. Pharm., 2007, 4, 323.
26. Aaker?y, C. B.; Hussain, I.; Desper, J.,. Cryst. Growth Des., 2006, 6, 474.
27. Caira, M. R.; Nassimbeni, L. R., Comprehensive Supramolecular Chemistry, Elsevier, Oxford, UK, 1996, 825.